|
|
|
|
|
|
| Targeted Modalities Set Elevated Standards For Precision | Article | By Anshul Gupte, PCI Pharma Services | Explore how targeted modalities like ADCs and TPDs are transforming precision medicine, unlocking new treatment opportunities, and overcoming development challenges to improve patient outcomes. |
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Heather Walters of CRB spends her time thinking about effective business and industrial sustainability and resource conservation. Meanwhile, Chief Editor Louis Garguilo maintains a position near the bottom of the list of interested parties. It made for great conversation. Uncovered were the current realities of sustainability in manufacturing facilities, and the importance of two components: electrification and digital twins. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Imprints On Oral Solid Dosage Forms | Case Study | By Jonas Schäfer and Lutz Drügemöller, Rottendorf Pharma GmbH | Selecting the right tablet imprinting technology is essential for product identification and compliance. Improve your print clarity, speed, and overall manufacturing efficiency. |
|
|
|
|
|
| Safely Scaling High Potency API Manufacturing | White Paper | Recipharm | Scaling HPAPI production demands disciplined containment and exposure control. Integrated operating models help manage risk while enabling compliant, reliable scale‑up. |
|
|
| Reshaping Drug Development With 3D Screen Printing | Q&A | Adare Pharma Solutions | Steven Facer and Laxxon Medical COO Klaus Kühne describe the capabilities of 3D screen printing for pharmaceutical production. Explore prototyping, IP protection, release profile possibilities, and more. |
|
|
|
|
|
| Enabling ADC Success | Dec. 1, 2026, 11:00 AM ET | This session explores the development, analytical, and manufacturing strategies supporting antibody-drug conjugate (ADC) and emerging conjugate programs. CDMOs will discuss challenges related to conjugation, CMC, developability, lyophilization, and complex payloads, including antibody-oligonucleotide conjugates. Attendees will gain insights into early risk mitigation, optimization strategies, and science-driven approaches that help improve program success and support efficient development and manufacturing. Learn more. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
